Abstract
Since 1995, many countries have been aiming to replace the natural immunity against varicella by a vaccine-induced immunity to protect against varicella and herpes zoster. While the frequency of varicella in childhood has been significantly reduced, in future, herpes zoster morbidity might increase in the elderly due to the weaker immunity post-vaccination and the absence of immunity boosting silent reinfections. In countries, where less than 90 % of children are covered by universal vaccination, varicella zoster virus (VZV) infection is not completely eradicated, but might move from childhood to the age of young adults who suffer from more serious complications. A special VZV vaccine against herpes zoster in adults aged >60 years has proven to be effective in many cases, but not all vaccinees. This might lead to problems regarding the acceptance of vaccination and delay rapid antiviral therapy to prevent the post-zosteric neuralgia. An efficacious-inactivated VZV vaccine to protect immunocompromised patients is still missing. VZV vaccines and vaccination strategies have to be optimised to avoid that the quality of life and cost savings from varicella reduction in childhood are offset by more VZV diseases in adults.
Similar content being viewed by others
References
Buxbaum S, Doerr HW, Allwinn R (2001) Epidemiological analysis of immunity against vaccine-preventable diseases: rubella, measles, mumps and chickenpox. Dtsch Med Wochenschr 126(46):1289–1293
Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:121–124
Abendroth A et al. (eds) (2010) Varicella-zoster virus. Curr Top Microbiol Immunol, vol. 342, Springer, New York
Gross G, Doerr HW (ed) (2006) Herpes zoster—recent aspects of diagnosis and control. Monographs in virology, vol. 26. Karger Press, Basel
Flatt A, Breuer J (2012) Varicella vaccines. Br Med Bull 103:115–127
Oxman MN (2010) Zoster vaccine—current status and future prospects. Clin Infect Dis 51:197–213
Allwinn R, Buxbaum S, Doerr HW (2006) Epidemiology of Herpes Zoster: what has changed? Monogr Virol 26:154–163
Van Hoek AJ, Melegano A, Gay N, Bilcke J, Edmunds WJ (2012) The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine 30:1225–1234
Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G (2000) Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18:2775–2778
Cheuk DK, Chiang AK, Lee TL, Chan GC, Ha SY (2011) Vaccines for prophylaxis of viral infections in patients with haematological malignacies. Cochrane Database Syst Rev CD006505
Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG (2012) Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev CD008858
Goldman PS, King PG (2012) Review of the US varicella vaccination program. Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the antilope valley varicella active surveillance project data. Vaccine (Epub ahead of print)
Cunningham AL, Breuer J, Dwyer DE, Gronow DW, Helme RD, Litt JC, Levin MJ, Macintyre CR (2008) The prevention and management of herpes zoster. Med J Aust 188:171–176
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Doerr, H.W. Progress in VZV vaccination? Some concerns. Med Microbiol Immunol 202, 257–258 (2013). https://doi.org/10.1007/s00430-013-0298-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00430-013-0298-x